Aquasol E

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Aquasol E

Property Description
Active ingredient alpha-Tocopherol (as alpha-Tocopheryl Acetate)
Form Oral solution (drops)
Pharmacological class Nutritional Supplement / Vitamin Preparation
General purpose Prevention and correction of Vitamin E deficiency
Origin / Type Synthetic, water-miscible formulation

Defining Aquasol E: Essential Vitamin and Pharmacological Class

Aquasol E is a well-recognized brand-name pharmaceutical preparation of the essential micronutrient Vitamin E (alpha-Tocopherol), formally classified as a Nutritional Supplement and Vitamin Preparation. The active ingredient is the synthetic derivative, alpha-Tocopheryl Acetate, which is recognized for its stability and effectiveness in replenishing the body's Vitamin E stores. The primary function of this component is to act as a powerful antioxidant, helping to protect cellular components from oxidative damage.


Formulation and Composition: The Water-Miscible Difference

The distinguishing feature of Aquasol E is its water-miscible oral solution form, which uses micellization technology to overcome a critical biological hurdle. While Vitamin E is naturally fat-soluble, this unique composition enables the synthetic alpha-Tocopheryl Acetate to disperse and dissolve readily in the aqueous environment of the gastrointestinal tract, unlike standard oil-based capsules.

This specialized preparation provides enhanced bioavailability, making Aquasol E a preferred option for specific patient groups, such as those whose ability to absorb fats—and thus, standard Vitamin E—is impaired. The focus of the preparation is the pediatric and adult population dealing with underlying malabsorption challenges.


Primary Role: Correcting Deficiency and Antioxidant Purpose

The central role of Aquasol E is to prevent or correct a confirmed deficiency of Vitamin E (hypovitaminosis E), a necessity frequently arising in the context of chronic fat malabsorption. The effective delivery of the active ingredient ensures the maintenance of the body's protective systems. The restoration of adequate antioxidant protection supports its role in maintaining tissue integrity, particularly in the nervous and muscular systems.

What side effects are possible with Aquasol E?

Possible Side Effects and Safety Information

The safety profile for the active ingredient in Aquasol E, alpha-Tocopherol, is defined by regulatory documents based on the dose and duration of exposure. Most adverse reactions are officially associated with significantly high daily intake (generally exceeding 400 IU or 1000 mg) and long-term use.

Adverse effects are categorized by System-Organ Class (SOC), with common reactions reported within the following systems:

  • Gastrointestinal Disorders: May include symptoms such as nausea, diarrhoea, and abdominal pain, with diarrhoea classified as Common at doses exceeding 1 gram daily.
  • Nervous Systems Disorders: May include headache and dizziness.
  • General Disorders: May include unusual tiredness or weakness (asthenia).

The most serious safety concern cited in regulatory labeling is the increased risk of bleeding or haemorrhage. This risk is due to the potential anti-Vitamin K activity of alpha-Tocopherol, particularly when taken at high doses. This serious risk necessitates specific constraints for vulnerable populations.

Population-Specific and Safety Constraints

Official safety documents include explicit cautions for several groups:

  • Patients on Anticoagulants: High doses may enhance the effect of blood-thinning medication (e.g., Warfarin), requiring careful monitoring of haemostasis parameters (PT/INR).
  • Vitamin K Deficiency: The medicine is cautioned against in individuals with pre-existing Vitamin K deficiency due to a heightened bleeding tendency.
  • Premature Infants: Specific concerns regarding high-dose use have been noted for low-birth-weight premature infants.

Use is contraindicated in individuals with a known hypersensitivity to the active substance or its excipients. The overall safety structure emphasizes that adverse events are primarily a function of excessive dose and duration rather than therapeutic-level usage.

Overdose and Emergency Response

Overdose and When to Seek Help — Official Regulatory Information for Aquasol E

Overdose Scope

Documented Overdose Presentations:

  • Gastrointestinal Disturbances: Transient gastrointestinal upset, including diarrhea and abdominal pain or intestinal cramps, is documented following intake of high daily doses.
  • Systemic Effects: Manifestations may also include fatigue, headache, and muscle weakness.

Physiological Systems Affected:

  • The primary system affected in severe overdosage is the Coagulation System, which may present as a prolonged Prothrombin Time (PT) or elevated International Normalized Ratio (INR).

Dose-Related or Exposure-Related Factors:

  • Overdose risks are principally linked to prolonged daily intake of amounts exceeding 1000 mg of alpha-tocopherol.

Population-Specific Overdose Notes:

  • An increased bleeding risk is specifically noted for patients concurrently receiving oral anticoagulants (e.g., Warfarin), as high-dose intake can potentiate the anticoagulant effect.

Emergency-Response Statements:

  • Treatment is mandated to be symptomatic and supportive, beginning with the cessation of the vitamin E supplement.
  • Vitamin K may be administered as a supportive measure if clinically significant bleeding or coagulopathy occurs.

When Immediate Medical Help is Required:

  • Regulatory guidance requires individuals to seek immediate medical attention and contact a physician or hospital if excessive overdosage is suspected.

Overdose Classifications (High-Level)

Severity classification (as defined in official documents):

  • Symptoms range from transient GI disturbances to the serious or life-threatening outcome of hemorrhage, which is the most critical documented complication.

Connection to the overall overdose profile: Regulatory documents define the overdose profile by listing common, reversible gastrointestinal manifestations alongside the primary serious risk of coagulopathy and potential hemorrhage. This severe risk dictates the mandatory instruction to seek immediate medical attention upon suspected excessive overdosage. The official response emphasizes supportive care, cessation of the product, and monitoring of the coagulation system.

Therapeutic Uses of Aquasol E

Aquasol E is applied across domains where additional symptomatic support is needed, is considered relevant in situations involving certain distressing symptoms, and is used for managing symptoms related to systemic imbalance that may be associated with Vitamin E deficiency. Clinical contexts for its use are marked by the presence of deficiency-related symptoms and conditions associated with episodic or fluctuating manifestations.

This medication may assist with easing discomfort across several categories of symptoms, including those related to neuromuscular discomfort (like weakness and loss of sensation) and challenges arising from nutritional malabsorption conditions (such as cystic fibrosis). The treatment is commonly used to help with providing essential, bioavailable support in clinical settings marked by temporary physiological imbalance in vulnerable patients, including premature infants and those with chronic ailments that heighten the body's need for Vitamin E.

This medication supports the patient during difficult episodes and contributes to improved comfort during periods of heightened symptoms. This medication is relevant for easing symptoms that create noticeable physiological strain and when temporary support for systemic imbalance is appropriate. This medication contributes to maintaining functional stability and easing the overall symptom load.

Quick Fact: Relief for Symptom Clusters

This medication is applied in addressing situations involving increased discomfort or tension, supporting general well-being during symptomatic phases.

Regulatory References

  1. NIH MedlinePlus

Eligibility and Restrictions for Use

Aquasol E (a water-soluble form of Vitamin E) is primarily indicated for individuals who have a diagnosed Vitamin E deficiency, particularly those with conditions that impair fat absorption. These conditions can include cystic fibrosis, chronic cholestatic liver disease, short bowel syndrome, or other malabsorption disorders. It may also be used in premature newborns with low Vitamin E levels.


Contraindications and Precautions

Aquasol E is contraindicated in patients with a known hypersensitivity or allergy to Vitamin E or any of the product's inactive components.

Use of high-dose Vitamin E requires caution in certain populations due to an increased risk of serious side effects. Patients should consult a healthcare provider before use if they have:

  • Bleeding disorders or an increased risk of bleeding (e.g., hemorrhagic stroke, bleeding peptic ulcer, hemophilia). High doses may increase this risk.
  • Are taking anticoagulant ("blood thinner") or antiplatelet medications (such as warfarin or aspirin), as Vitamin E can enhance their effects.
  • Have plans for surgery; a healthcare provider may advise discontinuing the supplement one month prior to the procedure.

While recommended daily amounts of Vitamin E are generally considered safe during pregnancy and breastfeeding, therapeutic-level supplementation should only be taken under the direction of a healthcare professional who can weigh the potential benefits against any risks.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Aquasol E (alpha-Tocopherol) is defined by its potential to affect the coagulation system and the pharmacokinetics of co-administered substances. High doses of alpha-Tocopherol may engage in a pharmacodynamic interaction with oral anticoagulants (such as Warfarin) and antiplatelet agents (e.g., Aspirin), increasing the risk of hemorrhage by opposing Vitamin K activity. The co-administration of the chemotherapy agent Ibrutinib is generally restricted due to the potential for enhanced antiplatelet effects.

Type of Interaction Interacting Substances Regulatory Statement
Altered Absorption Colestyramine, Orlistat, Mineral Oil These agents decrease the absorption of alpha-Tocopherol, requiring doses to be separated by at least two hours for proper uptake.
Altered Drug Levels Anticonvulsants, Ciclosporin Anticonvulsants (e.g., Phenytoin) may lower plasma Vitamin E levels via enzyme induction; high-dose Vitamin E may also decrease Ciclosporin serum concentration.
Timing Required Iron-Containing Medicines A necessary time interval should be maintained between doses to prevent mutual interference with the activity of iron supplements.

Furthermore, the interaction with Oestrogens (including oral contraceptives) has been associated with an increased risk of thrombosis. The overall regulatory structure highlights that many significant interaction risks are often dose-dependent and involve both additive effects and changes in clearance.

Mechanism of Action

️ Molecular Chain Termination and Cellular Defense

The primary mechanism involves alpha-Tocopherol acting as a chain-terminating antioxidant directly within the phospholipid membranes of cells. It engages its main targets, lipid peroxyl radicals ( LOOcdot), by donating a hydrogen atom to stabilize them. This action immediately halts the destructive chain reaction of lipid peroxidation, which is a key pathway of cellular damage. This protective mechanism is critical for maintaining the structural stability of tissues, such as the nervous and muscular systems, that exhibit high susceptibility to oxidative stress.


Neuromuscular Membrane Stabilization

The molecule's presence physically stabilizes the neuronal and muscle cell membranes and is required for maintaining their structural and functional integrity. This stabilization prevents the oxidative breakdown of polyunsaturated fatty acids (PUFAs), which is required for nerve conduction velocity and muscle function. The specialized, water-miscible formulation leverages micellization technology to ensure the molecule is efficiently absorbed and delivered to these tissues, a necessary prerequisite for the mechanism's systemic action.

Dosage and Administration Information

How to Use Aquasol E

The administration of this medication is based strictly on the specific instructions provided by a healthcare professional, as the required dose is highly individualized. This information details the official administration procedures and is not a substitute for your physician’s advice.


Official Administration Guidelines

Administration Component General Instruction
Route This medication is for oral use.
Dosing Must be administered only as directed by a physician. The prescribed dose for children must also be carefully determined by the physician.
Timing The dose may be taken with food or mixed with, or followed by, food or other liquid.
Capsules Swallow capsules whole. They must not be crushed, chewed, or broken.
Liquid Form The prescribed amount of liquid must be measured accurately using a calibrated measuring device only, not a household spoon.

Rules for Missed Doses

If you miss a dose of Aquasol E, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and continue with your regular dosing schedule. It is strictly instructed not to take two doses at the same time.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Aquasol E

Evidence for Correcting Confirmed Vitamin E Deficiency

The research base for Aquasol E's active ingredient, alpha-tocopherol, has been studied for use in contexts involving confirmed Vitamin E deficiency (Hypovitaminosis E). Research includes randomized controlled trials (RCTs) and systematic reviews, primarily monitoring changes in plasma alpha-tocopherol concentrations (biomarkers) and assessing deficiency-related neuromuscular symptoms. Studies monitored markers of antioxidant function and reported patterns where there was an observed shift in Vitamin E levels. However, data show patterns related to symptom changes that were sometimes mixed, and follow-up durations were often limited to short-to-intermediate timeframes.


Evidence for Deficiency in Malabsorption Syndromes

Aquasol E was evaluated in research exploring patient groups that have difficulty absorbing fat, such as those with cystic fibrosis or cholestasis. Studies explored the unique water-miscible formula by measuring its absorption efficiency compared to standard preparations through specialized pharmacokinetic (PK) studies. These studies monitored absorption patterns, finding data that show differing levels of uptake compared to traditional forms. Research has explored short-term symptom changes, and studies monitored the association with maintaining serum Vitamin E levels in these observed populations.


Study Limitations and Research Gaps

Research was conducted across special populations, including premature infants and children with complex malabsorption conditions. Results apply only to the specific populations studied, but research describes the observed patterns in these defined groups. However, evidence is limited for certain long-term effects, and sustained functional outcomes over many years are not fully established. Comparative evidence is lacking against other specialized Vitamin E formulations, and sample sizes were often modest in studies involving rare fat malabsorption conditions.

Key Studies & References

  1. Vitamin E (Tocopherol) Test - MedlinePlus

Frequently Asked Questions (FAQ)

Common questions about Aquasol E (FAQ)


Q: How should Aquasol E be stored, and is it sensitive to light or moisture?

According to official product information, Aquasol E should be kept in its original, tightly closed container at room temperature (between 68 F and 77 F). The labeling emphasizes the need to store it away from excess moisture, heat, and direct light to maintain its stability.


Q: What type of conditions or symptoms is Aquasol E prescribed to treat?

Regulatory documents indicate that Aquasol E is indicated for the prevention and treatment of a confirmed Vitamin E deficiency (hypovitaminosis E). It is particularly recommended for individuals with malabsorption disorders, such as cystic fibrosis or chronic liver disease, which impair the absorption of standard fat-soluble vitamins. This specialized formula is designed to promote the absorption of the vitamin in these patient groups.


Q: Can Aquasol E interact with blood thinners like Warfarin, and what are the risks?

Official information confirms that high doses of Aquasol E may interact with anticoagulants (blood thinners), such as Warfarin. This is due to the potential for the vitamin to oppose the action of Vitamin K, increasing the risk of bleeding (hemorrhage). Therefore, monitoring of blood coagulation parameters (e.g., PT/INR) is necessary when these products are used together.


Q: Can children or premature infants use Aquasol E, and are there any specific safety warnings for them?

The product can be prescribed for children, but the dose must always be carefully determined by a physician. Official safety documents include specific cautions regarding high-dose use in low-birth-weight premature infants. All decisions regarding use in children, including safety warnings, should be reviewed with a healthcare professional.


Q: Does the special water-miscible formula of Aquasol E mean it can be mixed with any beverage?

Official administration guidelines state that the dose may be taken with food or mixed with, or followed by, food or other liquid. Specific regulatory sources do not list every acceptable or restricted beverage. Questions about specific beverages should be directed to the prescribing healthcare professional or a pharmacist.


Q: What are the signs or symptoms of a Vitamin E deficiency that would require taking this supplement?

Vitamin E deficiency symptoms often manifest in the nervous and muscular systems. These symptoms can include muscle weakness, problems with movement and coordination (ataxia), vision disturbances, and a general feeling of fatigue. This deficiency is most commonly encountered in people who have an underlying medical condition that prevents them from properly absorbing fats.


Q: Is Aquasol E a natural or synthetic form of Vitamin E?

Aquasol E contains the active ingredient alpha-Tocopheryl Acetate, which is the synthetic (man-made) derivative of Vitamin E. This form is used in the product for its stability and effectiveness in replenishing the body's vitamin stores.

How should Aquasol E be stored and disposed of?

Storage and Disposal Requirements for Aquasol E

The official labeling for Aquasol E (alpha-Tocopheryl Acetate oral solution) mandates specific conditions to maintain product stability and safety.

Storage Conditions

The product must be stored at Controlled Room Temperature, which is generally defined as 20 C to 25 C (68 F to 77 F), with permissible excursions. To protect the contents, Aquasol E must be kept in a closed container and stored away from heat, moisture, and direct light.

Safety and Disposal

It is mandatory to keep Aquasol E out of the reach of children. When discarding, the medicine must be safely thrown away when no longer needed. Official guidelines advise against throwing the product into wastewater or household trash and recommend consulting a pharmacist or local waste disposal company for proper instructions.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Aquasol E found in:

A-Z Index: